Use of cyclic anabaenopeptin-type peptides for the treatment of a condition wherein inhibition of carboxypeptidase U is beneficial, novel anabaenopeptin derivatives and intermediates thereof

Details for Australian Patent Application No. 2004283643 (hide)

Owner AstraZeneca AB

Inventors Quinn, Ron; Campitelli, Marc; Hyde, Edward; Neve, Juliette; Buchanan, Malcolm; Carroll, Anthony; Polla, Magnus; Bjorquist, Petter

Agent Davies Collison Cave

Pub. Number AU-B-2004283643

PCT Pub. Number WO2005/039617

Priority 0302853-7 29.10.03 SE

Filing date 28 October 2004

Wipo publication date 6 May 2005

Acceptance publication date 10 July 2008

International Classifications

A61K 38/00 (2006.01) Medicinal preparations containing peptides

C07K 7/06 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

C07K 7/54 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

C07K 7/56 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

Event Publications

18 May 2006 PCT application entered the National Phase

  PCT publication WO2005/039617 Priority application(s): WO2005/039617

10 July 2008 Application Accepted

  Published as AU-B-2004283643

6 November 2008 Standard Patent Sealed

27 May 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004283644-A two-step system for improved initial and final characteristics of a biomaterial

2004283635-Multiple active agents such as anthelmintics sustained release delivery